This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hess, A. D. Articles by Dawson, J. R. Search for Related Content PubMed PubMed Citation Articles by Hess, A. D. Articles by Dawson, J. R.

Inhibition of Human Lymphoblastoid Cell Line Proliferation by Ascites Fluids from Ovarian Cancer Patients¹

Division of Immunology, Department of Microbiology and Immunology [A. D. H., J. R. D.], and Department of Obstetrics and Gynecology [S. A. G.], Duke University Medical Center, Durham, North Carolina 27710

Ascitic fluids from ovarian cancer patients which contained a component (lymphocyte-inhibitory activity) that inhibited the blastogenic responses of normal lymphocytes were tested for their effect on established lymphoblastoid cell lines. These ascites fluids inhibited proliferation as measured by [³H]thymidine uptake and cell growth in vitro of two different B- (SB and IM-1) and two different T- (HSB and CEM) lymphoblastoid cell lines but were not cytotoxic. No difference in the sensitivity of T- and B-lymphoblastoid cell lines to the active component in the ascites fluids could be demonstrated. In contrast, established nonlymphoid cell lines (HEp-2, oligodendroglioma, and bladder tumor cell lines) were unaffected by the ascites fluids. Two different preparations of partially purified lymphocyte inhibitory activity from these ascites fluids also inhibited lymphoblastoid cell line proliferation. In addition, both B- and T-lymphoblastoid cell lines absorbed and/or metabolized the lymphocyte-inhibitory activity at 37° but not at 4°. These data suggest that the inhibition of lymphoblastoid cell line proliferation and the inhibition of the blastogenic responses of normal lymphocytes by the ascites fluids are attributable to the same or similar factors.

¹ This investigation was supported in part by American Cancer Society Grant IM-94, the Ettie Stettheimer Memorial Fund, and NIH Grant CA-14049.

² NIH Postdoctoral Fellow on Training Grant T32 CA-09058-03. Present address: Oncology Center 3-130, Johns Hopkins Hospital, Baltimore, Md. 21205. To whom requests for reprints should be addressed.

Received 2/22/80. Accepted 9/ 5/80.